

**CONFIDENTIAL MINUTES OF
MEDICAL COMMITTEE MEETING**

INSTITUTIONAL BIOSAFETY COMMITTEE

**Tuesday, 05/19/2026 12:08 PM
MSBII 5A116**

Chairperson

Mingtao Zeng, PhD

Board Members

Anthony W Baird, DSc
Jeana E. Barrow, DVM
Huanyu Dou, MD
Pallavi Dubey, PhD
Ivan E Flores, BS
Daniel Gonzales, BA

Administrative Staff

Amanda Ortiz
Myrna Arvizo

MEMBERS PRESENT
Anthony W Baird, DSc, Jeana E. Barrow, DVM, Huanyu Dou, MD, Pallavi Dubey, PhD, Ivan E Flores, BS, Daniel Paul Gonzales, BMS, Mingtao Zeng, PhD
MEMBERS ABSENT
N/A
STAFF PRESENT
Myrna Arvizo, BMS, CIP, CHRC, Amanda Diazdeleon
GUESTS PRESENT
Hector Riveroll (Safety Services) from EPCC

CALL TO ORDER

Mingtao Zeng, PhD called the meeting to order at 12:08 p.m. Quorum is 5 members. 7 members are present at the call to order, including scientific, non-scientific and non-affiliated members. 6 members present at conclusion.

All proceedings and discussion in the upcoming meeting are confidential and should not be discussed outside of the meeting. Additionally, any member who has a conflict of interest that would preclude making an objective determination about a study should recuse him/herself from voting on the study.

A draft of the meeting minutes from 04/21/2026 was distributed for review on 05/12/2026. There were no

controversial entries or objections. A motion to approve the meeting minutes as written was made by AB and seconded by JB. The committee voted unanimously to approve the minutes.

The meeting was adjourned at 1:21 p.m.

NEW EVENTS

Safety Services laboratory inspections was recommended by the Committee following review of the previous non-compliance inquiries. The PI of this protocol is an IBC member and was asked to recuse herself from the meeting during this discussion.

MISCELLANEOUS

N/A

3-YEAR RENEWALS

IBC# 23005

Full Renewal Expiration Date: 05/31/2029

Jorge C Borges, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has revised the summary in section 5.1.

MEMBER COMMENTS:

Comment:

Dr. Borges added a summary to the study which describes what the experiment aims to do. They will be evaluating Milvexian in individuals who recently experienced acute coronary syndrome (ACS). The study aims to determine if Milvexian when combined with anticoagulants can reduce the risk of major adverse cardiovascular events (MACE) compared to a placebo. This study will hopefully provide more robust evidence on its effectiveness in reducing the risk of cardiovascular events in individuals with recent ACS.

I recommend approval as is.

Comment:

Understood that this protocol is being taken over from one researcher to another. There was no concern with the original protocol, so no concerns from Safety or Biological Safety Officer on this three year renewal.

RECOMMENDATIONS: Approve

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: **7** [For: **7** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

IBC# 23005

Full Renewal Expiration Date: 05/31/2026

Jorge C Borges, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Protocol Type: Three Year Renewal

PI Request: Use of

Space: MSBII 4B506 D&E

Biological Agents: Human Blood, Body Fluids

Chemicals: N/A

Controlled Substances: N/A

Biosafety Level: BSL-2

Hazardous Shipping: Complete

On-Campus Transport Training: Complete

Recombinant or Synthetic Nucleic Acids: Not involved

Training Compliance: PI and all key personnel are current on required LSE, COI, and Financial Disclosure trainings.

MEMBER COMMENTS:

Comment:

Dr. Borges submitted a 3-year renewal for a protocol under his supervision, which will allow Clinical Laboratory Tests to be performed as required by the protocols of clinical research studies under the Principal Investigator's supervision. The study assessments require the collection, processing, and shipment of blood and saliva samples. There have not been any changes to the protocol from what I can tell, and I support approval as is.

Comment:

Section 9 for Safety is covered well for blood, urine, and saliva, both administrative controls and engineered controls. Section 5.1 Should explain research much better. Only the "how" is partially explained. The "why" and process for a lay person to understand is completely missing.

RECOMMENDATIONS: Additional Information Required

STIPULATIONS:

Section 5.1 needs to explain the research in terms that can be understood by someone without a scientific background. The section currently only partially explains what will be done ("how"), but does not clearly explain the purpose of the research ("why") or the overall process. Additional detail should be added so a lay person can understand the goals, importance, and procedures of the study.

SUBMISSION OUTCOME: Additional Information Required

IBC# 14005

Full Renewal Expiration Date: 05/31/2029

Munmun Chattopadhyay, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has responded to the concerns of the reviewer. Please see the Submission Response Form and revised Study Application.

MEMBER COMMENTS:

Comment:

The PI has addressed all the stipulations. No further comments.

Comment:

No further comments.4. Reviewed prior to being assigned again. No concerns from Safety Services and/or Biological Safety Officer.

RECOMMENDATIONS: Approve

MOTION AND VOTE: Total Members Voting: 7

[For: 7 Absent: 0 Against: 0 Conflict of Interest: 0 Not Present: 0 Abstained: 0]

SUBMISSION OUTCOME: Approved

IBC# 14005

Full Renewal Expiration Date: 05/31/2026

Munmun Chattopadhyay, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

This is a Three Year Renewal, the PI is requesting

Space: MSBI 4209, 4210, 4213, 1502, 1511

Biological Agents: Human Tissue, Cell Lines

Chemicals: Streptozotocin, Zamboni's Fixative

Controlled Substances: Buprenorphine SR

Biosafety Level: BSL-2

Hazardous Shipping & On-Campus Transport Training: Yes to both

Recombinant or Synthetic Nucleic Acids: Yes

Training Compliance: PI and all key personnel are current on required LSE, COI, and Financial Disclosure trainings

MEMBER COMMENTS:**Comment:**

Section 2.1: Protocol indicates "continuation without changes," however, multiple complex components are described (viral vectors, human tissue, animal work, transport). The Pi must clarify whether the activities remain unchanged from prior approval or have to be updated.

Section 4.4: Description does not summarize outcomes, scale of work, or progress. It should include justification for continued work.

Section 8.3: Statement " HSV vector is very safe to use" should be changed. It should reflect handling requirements.

Section 9.5: appropriate units should be used

Section 5.5 (p.5): Incomplete shipping information should also include classification and packaging requirements

Section 6.2: Chemical use description lacks procedural details

Section 6.4: Buprenorphine (controlled) and bupivacaine (non-controlled) are described together. The controlled substance should be classified separately.

Comment:

In section 6.4, in the concentration column, the dose of buprenorphine SR is listed. Please list the concentration on the bottle. No concerns for changes and renewal of this protocol from Safety Services and/or Biological Safety Officer.

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: 1. IBC Protocol 3-Year Renewal form Section 2.1: Protocol indicates "continuation without changes," however, multiple complex components are described (viral vectors, human tissue, animal work, transport). The Pi must clarify whether the activities remain unchanged from prior approval or have to be updated.

2. In the IBC Protocol 3 Year Renewal form Section 4.4: Description does not summarize outcomes, scale of work, or progress. It should include justification for continued work.

3. Section 5.5 (p.5): Incomplete shipping information should also include classification and packaging requirements

4. Section 6.2: Chemical use description lacks procedural details

5. Section 6.4: Buprenorphine (controlled) and bupivacaine (non-controlled) are described together. The controlled substance should be classified separately.

6. Section 6.4, in the concentration column, the dose of buprenorphine SR is listed. Please list the concentration on the bottle.

7. Section 8.3: Statement " HSV vector is very safe to use" should be changed. It should reflect handling requirements.

8. Section 9.5: appropriate units should be used

SUBMISSION OUTCOME: Additional Information Required

AMENDMENTS

IBC# 26004

Full Renewal Expiration Date: 10/31/2028

Hareesh Babu Bhaskaran Nair, PhD/TTUHSC El Paso - SOM - MTM-CoE in Cancer

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has requested additional cell lines that have been added to section 7.8.

MEMBER COMMENTS:

Comment:

No comments or concerns, very thorough protocol.

Comment:

No comments or concerns on this protocol change from Safety Services and/or Biological Safety Officer.4. Human cancer cell lines and tumor-like 3D cultures are exposed to experimental medicines and observed whether these exposures seek right target attachment and harmful signal shut down. *Additional human-derived cancer and normal cell lines that were not explicitly listed in the original application are added.* Promising candidate material is then evaluated in mouse models, monitoring tumor-response and harmful side effects. Animals are housed in an accredited facility with veterinary oversight. Standard genetic tools like plasmid DNA or non-replicating viral vectors may be used to manipulate tumor response and signal change. Organisms that cause disease in health people are not used. Select agents are also not used. All work with human-derived and gene-transfer tools is performed under Biosafety Level-2 (BSL-2) practices. Biologic waste is disposed of using appropriate practices. All measures minimize risk to researchers, community, and environment.

RECOMMENDATION IS FOR APPROVAL

RECOMMENDATIONS: Approve

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: **7** [For: **7** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

IBC# 26005

Full Renewal Expiration Date: 01/31/2029

Raja Veerapandian/TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI is requesting to add

1. Lactobacillus casei and additional Streptococcus strains.
2. Additional streptococcal, candidal and BCG genes in rDNA cloning part.
3. Dr. Justin R. Kaspar, The Ohio State University as a source for receiving some Streptococcus strains through IMTA request.
4. W. Henry Boom, Case Western Reserve University as a source for receiving some cell lines through IMTA request.
5. Added cell lines J774A.1 - TIB-67; COS-7 - CRL-1651.

MEMBER COMMENTS:

Comment:

TTUHSC EP IBC Meeting Minutes - 05/19/2026

Page 1 of 2

Confidential Medical Committee: This document and all contents (including any attachments) is for the sole use of the intended recipient(s) and contains confidential or privileged information and is not to be forwarded, disclosed or otherwise given to others unless expressly authorized in writing by the TTUHSC El Paso Institutional Biosafety Committee. If you are not the intended recipient, please contact the El Paso Institutional Biosafety Committee at 915-215-4295 and destroy all documents received.

Proper biosafety issue has been addressed in the amendment. There are no other concerns.

Comment:

No concerns from Safety Services and/or Biological Safety Officer on these changes to protocol.

RECOMMENDATIONS: Approve

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed this protocol at their full board meeting and granted unrestricted approval.

Total Members Voting: **7** [For: **7** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]

SUBMISSION OUTCOME: Approved

INITIAL REVIEWS

IBC# 26010

Full Renewal Expiration Date:

Alex Gonzalez DDS/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Protocol Type: Initial Application

Space: MSBII 4B406 (a correspondence was sent to Jessica Kenerson requesting confirmation of space usage)

Biological Agents: Human Blood (**should "Human Tissue" be selected**)

Chemicals: None listed

Controlled Substances: None listed

Biosafety Level: BSL-2

Hazardous Shipping: Not listed

On-Campus Transport Training: Completed by those listed

Recombinant or Synthetic Nucleic Acids: Not involved

Training: PI and all key personnel are current on required LSE, COI, and Financial Disclosure trainings.

Of the nine comments made by the primary reviewer, only six were forwarded to the PI.

Section 1.3: of the Initial Review Submission form states (IBC - type N?A)

Section 4.1: The application process allows only one committee selection, and the PI correctly submitted this as an IBC application.

Comment 9.1 should be reviewed and discussed by the committee.

MEMBER COMMENTS:

Comment:

Sec 4.1: Submitted as IBC-only, but likely needs IRB review too since the protocol includes patient studies, etc.

Sec 5.1: This study has been described as an in vitro study using extracted teeth. It also includes active patient treatment and recruitment. Study design is internally inconsistent.

Incorrect risk statement for human subjects - page 13: This protocol states there is minimal risk to the subjects. However, the root canal procedure is involved.

Sec 9.1–9.4: Underestimation of biosafety risk. There is no estimated risk of HBV/HIV/CMV status. There is also no reflected risk of BSL2 risk level for human-derived material.

Sec 9.2–9.4: Incomplete biosafety procedures: This section is missing Aerosol risk during instrumentation, Sharps hazard mitigation, and decontamination workflow.

Sec 7.2: Residual blood is not considered as potentially infectious material. Proper classification must be done.

Sec 1.3: Lay summary is missing and listed as N/A

Sec 5.6: Movement of extracted teeth between locations is missing: all handling/labeling procedures and

containment methods.

Protocol page 13. The data confidentiality is unclear. It states that no PHI will be collected, but it mentions collecting demographics and medical history. This is a discrepancy

Comment:

Agree with IBC member reviewing protocol and comments. Items in Section 9 in the member comments do need addressed for Safety Services and Biological Safety Officer as well as reviewer.

Areas of use need additional information. Which bay (letter) in this lab will be in use, and biosafety cabinets are in additional rooms at this location. If coordinated with Office of Research, room 4B401 would be in use for higher containment as this is where the biosafety cabinet is located.

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: Sec 5.1: This study has been described as an in vitro study using extracted teeth. It also includes active patient treatment and recruitment. Study design is internally inconsistent.

2. Sec 5.6: Movement of extracted teeth between locations is missing: all handling/labeling procedures and containment methods.

3. Sec 7.2: Residual blood is not considered as potentially infectious material. Proper classification must be done.

4. Sec 9.2–9.4: Incomplete biosafety procedures: This section is missing Aerosol risk during instrumentation, Sharps hazard mitigation, and decontamination workflow.

5. Incorrect risk statement for human subjects - page 13: This protocol states there is minimal risk to the subjects. However, the root canal procedure is involved.

6. Protocol page 13. The data confidentiality is unclear. It states that no PHI will be collected, but it mentions collecting demographics and medical history. This is a discrepancy

SUBMISSION OUTCOME: Additional Information Required

EXPEDITED REVIEW

IBC# 23005

Full Renewal Expiration Date: 05/31/2026

Jorge C Borges, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This amendment originally came in 10/21/2025. There were two minor stipulations that had not been addressed. After resubmitting the minor questions have been addressed in the revised application.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

ADMINISTRATIVE-ANNUAL STATUS REPORTS

IBC# 24007

Full Renewal Expiration Date: 05/31/2027

Nathan Holland, PhD/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does not include shipper or on-campus training. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

TTUHSC EP IBC Meeting Minutes - 05/19/2026

Page 1 of 2

Confidential Medical Committee: This document and all contents (including any attachments) is for the sole use of the intended recipient(s) and contains confidential or privileged information and is not to be forwarded, disclosed or otherwise given to others unless expressly authorized in writing by the TTUHSC El Paso Institutional Biosafety Committee. If you are not the intended recipient, please contact the El Paso Institutional Biosafety Committee at 915-215-4295 and destroy all documents received.

IBC# 19004

Full Renewal Expiration Date: 05/31/2028

Irene Sarosiek, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does include shipper and on-campus training. This training is complete for those listed in section 5.5 and 5.6. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

ADMINISTRATIVE-AMENDMENTS

IBC# 23006

Full Renewal Expiration Date: 01/30/2027

Jonathan Lavezo, MD/TTUHSC El Paso - SOM - Pathology

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Personnel change to add Natalie Franco, Karla Salazar and Ezequiel Salazar and removal of Mallkuntla and Sarah Martinez. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 26005

Full Renewal Expiration Date: 01/31/2029

Raja Veerapandian/TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Sheryl Rodriguez. COI, FD, and LSE are complete. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 19004

Full Renewal Expiration Date: 05/31/2028

Irene Sarosiek, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is a correction to remove Adriana Acosta from the application sections 5.5 and 5.6. A new license will not

be issued as Adriana was removed from section 3 previously and is not listed on the IBC license.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 23006

Full Renewal Expiration Date: 01/30/2027

Jonathan Lavezo, MD/TTUHSC El Paso - SOM - Pathology

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Eli Montero. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 24008

Full Renewal Expiration Date: 08/31/2027

Cynthia Perry, PhD/TTUHSC El Paso - SOM - Admissions

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment: 1. On 8/7/2025, an amendment was submitted adding Dr. Mayer as the Co-PI however, Dr. Mayer was incorrectly listed as the PI. This is to correct that error and properly add Dr. Perry as the PI.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

TERMINATIONS

N/A

BSO REPORT

No report was submitted by Safety Services, no deficiencies were reported.